This article first appeared on GuruFocus.
Novo Nordisk (NVO) said it has entered a partnership with Anthropic to expand the use of artificial intelligence in drug research and software development.
The agreement is aimed at helping the Wegovy maker address key research challenges and potentially shorten parts of the medicine development process.
As part of the collaboration, Novo Nordisk plans to evaluate Anthropic’s Claude Science platform, a tool designed to support scientific research workflows. The company said the initial work will focus on applying AI to selected research and development activities.
Novo Nordisk also intends to use Anthropic’s AI models to support software engineering efforts across the organization as it broadens adoption of AI technologies. The Danish drugmaker has increasingly incorporated AI into its operations and earlier this year formed a separate partnership with OpenAI focused on drug discovery and other business functions.
The companies said the partnership includes data governance measures and human oversight. Novo Nordisk CEO Mike Doustdar said the deal supports the company’s goal of becoming a more AI-focused healthcare organization, while Anthropic CEO Dario Amodei said advanced AI tools could help researchers improve the pace of scientific work.